Skip to main content
Top
Published in: Diabetologia 3/2004

01-03-2004 | Short Communication

Silent myocardial infarction and its prognosis in a community-based cohort of Type 2 diabetic patients: the Fremantle Diabetes Study

Authors: T. M. E. Davis, P. Fortun, J. Mulder, W. A. Davis, D. G. Bruce

Published in: Diabetologia | Issue 3/2004

Login to get access

Abstract

Aims/hypothesis

Our study investigated the prognosis of Type 2 diabetic patients with silent myocardial infarction in a community-based cohort.

Methods

We analysed data from 1269 patients with Type 2 diabetes mellitus from a community-based observational study of diabetes care, control and complications. Silent myocardial infarction was defined as Q waves (Minnesota codes 1.1, 1.2) on a baseline electrocardiogram in the absence of a history or symptoms of CHD.

Results

Silent myocardial infarction was present in 3.9% of patients, or 44% of all Q-wave myocardial infarctions. The patients were subdivided into those with (i) no clinical or Q-wave evidence of myocardial infarction (Group 1), (ii) silent myocardial infarction (Group 2), (iii) self-reported CHD but no Q waves (Group 3), and (iv) self-reported CHD and Q waves (Group 4). Compared to Groups 3 and 4, Group 2 patients were more likely to be women, less likely to have smoked, and had higher serum HDL-cholesterol concentrations and higher blood pressure. Over an average of seven years, and after adjusting for other independent predictors of death, all-cause and CHD mortality were similar in Groups 1 and 2 and greater (twofold for all-cause and fourfold for CHD mortality) in Groups 3 and 4.

Conclusions/interpretation

Silent myocardial infarction is common in Type 2 diabetes and has a prognosis similar to that in patients without a history of CHD or Q waves.
Literature
1.
go back to reference Medalie JH, Goldbourt U (1976) Unrecognized myocardial infarction: five-year incidence, mortality, and risk factors. Ann Intern Med 84:526–531CrossRefPubMed Medalie JH, Goldbourt U (1976) Unrecognized myocardial infarction: five-year incidence, mortality, and risk factors. Ann Intern Med 84:526–531CrossRefPubMed
2.
go back to reference Yano K, MacLean CJ (1989) The incidence and prognosis of unrecognized myocardial infarction in the Honolulu, Hawaii, Heart Program. Arch Intern Med 149:1528–1532CrossRefPubMed Yano K, MacLean CJ (1989) The incidence and prognosis of unrecognized myocardial infarction in the Honolulu, Hawaii, Heart Program. Arch Intern Med 149:1528–1532CrossRefPubMed
3.
go back to reference Nadelmann J, Frishman WH, Ooi WL et al. (1990) Prevalence, incidence and prognosis of recognized and unrecognized myocardial infarction in persons aged 75 years or older: The Bronx Aging Study. Am J Cardiol 66:533–537CrossRefPubMed Nadelmann J, Frishman WH, Ooi WL et al. (1990) Prevalence, incidence and prognosis of recognized and unrecognized myocardial infarction in persons aged 75 years or older: The Bronx Aging Study. Am J Cardiol 66:533–537CrossRefPubMed
4.
go back to reference Airaksinen KE (2001) Silent coronary artery disease in diabetes—a feature of autonomic neuropathy or accelerated atherosclerosis? Diabetologia 44:259–266CrossRefPubMed Airaksinen KE (2001) Silent coronary artery disease in diabetes—a feature of autonomic neuropathy or accelerated atherosclerosis? Diabetologia 44:259–266CrossRefPubMed
5.
go back to reference Janand-Delenne B, Savin B, Habib G, Bory M, Vague P, Lassmann-Vague V (1999) Silent myocardial ischemia in patients with diabetes: who to screen. Diabetes Care 22:1396–1400CrossRefPubMed Janand-Delenne B, Savin B, Habib G, Bory M, Vague P, Lassmann-Vague V (1999) Silent myocardial ischemia in patients with diabetes: who to screen. Diabetes Care 22:1396–1400CrossRefPubMed
6.
go back to reference Davis TM, Zimmet P, Davis WA, Bruce DG, Fida S, Mackay IR (2000) Autoantibodies to glutamic acid decarboxylase in diabetic patients from a multi-ethnic Australian community: the Fremantle Diabetes Study. Diabetic Med 17:667–674CrossRefPubMed Davis TM, Zimmet P, Davis WA, Bruce DG, Fida S, Mackay IR (2000) Autoantibodies to glutamic acid decarboxylase in diabetic patients from a multi-ethnic Australian community: the Fremantle Diabetes Study. Diabetic Med 17:667–674CrossRefPubMed
7.
go back to reference Rose GA, Blackburn H, Gillum RF, Prineas RJ (1982) Cardiovascular survey methods, 2nd edn. World Health Organization, Geneva Rose GA, Blackburn H, Gillum RF, Prineas RJ (1982) Cardiovascular survey methods, 2nd edn. World Health Organization, Geneva
8.
go back to reference Kannel WB, Dannenberg AL, Abbott RD (1985) Unrecognized myocardial infarction and hypertension: the Framingham Study. Am Heart J 109:581–585CrossRefPubMed Kannel WB, Dannenberg AL, Abbott RD (1985) Unrecognized myocardial infarction and hypertension: the Framingham Study. Am Heart J 109:581–585CrossRefPubMed
9.
go back to reference Scheidt-Nave C, Barrett-Connor E, Wingard DL (1990) Resting electrocardiographic abnormalities suggestive of asymptomatic ischemic heart disease associated with non-insulin-dependent diabetes mellitus in a defined population. Circulation 81:899–906CrossRefPubMed Scheidt-Nave C, Barrett-Connor E, Wingard DL (1990) Resting electrocardiographic abnormalities suggestive of asymptomatic ischemic heart disease associated with non-insulin-dependent diabetes mellitus in a defined population. Circulation 81:899–906CrossRefPubMed
10.
go back to reference Ashley EA, Raxwal V, Froelicher V (2001) An evidence-based review of the resting electrocardiogram as a screening technique for heart disease. Prog Cardiovasc Dis 44:55–67CrossRefPubMed Ashley EA, Raxwal V, Froelicher V (2001) An evidence-based review of the resting electrocardiogram as a screening technique for heart disease. Prog Cardiovasc Dis 44:55–67CrossRefPubMed
Metadata
Title
Silent myocardial infarction and its prognosis in a community-based cohort of Type 2 diabetic patients: the Fremantle Diabetes Study
Authors
T. M. E. Davis
P. Fortun
J. Mulder
W. A. Davis
D. G. Bruce
Publication date
01-03-2004
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 3/2004
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-004-1344-4

Other articles of this Issue 3/2004

Diabetologia 3/2004 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.